Boston Scientific to participate in TD Cowen's 46th Annual Health Care Conference
Rhea-AI Summary
Boston Scientific (NYSE: BSX) will participate in TD Cowen's 46th Annual Health Care Conference on Tuesday, March 3, 2026. Mike Mahoney, chairman and CEO, and Kenneth Stein, M.D., senior VP and global chief medical officer, will join a 30-minute Q&A at ~9:10 a.m. ET.
A live webcast and replay will be available at the company investor website, with the replay posted about one hour after the session ends.
Positive
- None.
Negative
- None.
News Market Reaction – BSX
In the Feb 13 session, BSX gained 0.82%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| 2026-02-04 | Earnings results | Positive | -17.6% | Strong Q4 and 2025 results with raised 2026 guidance and product approvals. |
| 2026-01-15 | Major acquisition | Neutral | -4.0% | Agreement to acquire Penumbra in a large cash-and-stock transaction. |
| 2026-01-12 | Bolt-on acquisition | Neutral | -2.0% | Agreement to acquire Valencia Technologies and its FDA-approved eCoin system. |
| 2026-01-02 | Conference & call | Neutral | -0.7% | J.P. Morgan conference appearance and scheduled Q4 and 2025 results call. |
| 2025-12-10 | Management & product | Neutral | +0.2% | CathVision board change and ECGenius System Version 3.5 commercial release. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows a notable selloff on fundamentally strong earnings, while acquisition and conference headlines have driven only modest, generally aligned moves.
Over the past few months, Boston Scientific has combined solid execution with active deal-making. On Feb 4, 2026, it reported strong Q4 and full-year 2025 results and raised 2026 guidance, yet the stock fell 17.59%. In January, it announced a $14.5 billion Penumbra acquisition and a smaller Valencia Technologies deal, both with limited share reaction. Earlier, participation in the J.P. Morgan Healthcare Conference and a CathVision-related update also produced muted moves. Today’s TD Cowen conference notice fits this pattern of routine investor-engagement news.
AI-generated analysis. How Rhea-AI works. Not financial advice.
A live webcast and replay of the session will be accessible at https://investors.bostonscientific.com. The replay will be available approximately one hour following the completion of the event.
About Boston Scientific
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and follow us on LinkedIn.
CONTACTS:
Chanel Hastings
Media Relations
+1 (508) 382-0288
Chanel.Hastings@bsci.com
Lauren Tengler
Investor Relations
+1 (508) 683-4479
BSXInvestorRelations@bsci.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/boston-scientific-to-participate-in-td-cowens-46th-annual-health-care-conference-302687094.html
SOURCE Boston Scientific Corporation